Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

RAFAEL HOLDINGS, INC.

(RFL)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Rafael : Announces Inducement Grant Under NYSE Rule 303A.08

04/16/2021 | 05:01pm EDT

NEWARK, N.J., April 16, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), today announced that on April 15, 2021 it made a grant to William Conkling of options to purchase 118,409 shares of Class B common stock of the Company with an exercise price equal to $40.85, the closing price of the Class B common stock on April 14, 2021, the trading day prior to the grant.

The options shall vest as follows:  29,602 on April 15, 2022; 2,467 monthly for thirty-five months commencing on May 15, 2022; and 2,462 on April 15, 2025. 

The options were granted under Rafael's 2018 Equity Incentive Plan, which was amended and restated to create an additional pool of 118,409 shares of Rafael's Class B common stock to be used exclusively for the grant of inducement awards in compliance with New York Stock Exchange Rule 303A.08 ("Rule 303A.08").  The option grant was approved by the Compensation Committee of the Board of Directors and was offered as a material inducement to Mr. Conkling's hiring as Chief Commercial Officer of the Company in reliance on the employment inducement exemption under Rule 303A.08. Mr. Conkling joined the Company on March 15, 2021.

The option grant described above will be subject to the terms of the 2018 Equity Incentive Plan, as amended and restated.  

About Rafael Holdings, Inc.:
Rafael Holdings is focused on development of novel cancer therapies.  The company is a significant investor in two clinical stage oncology companies, Rafael Pharmaceuticals, Inc. and LipoMedix Pharmaceuticals Ltd.  Through its wholly owned Barer Institute subsidiary, the company is developing a pipeline of compounds focused on the regulation of cancer metabolism.  For more information, visit www.rafaelholdings.com.

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/rafael-holdings-announces-inducement-grant-under-nyse-rule-303a08-301270794.html

SOURCE Rafael Holdings, Inc.


© PRNewswire 2021
All news about RAFAEL HOLDINGS, INC.
04/16RAFAEL  : Announces Inducement Grant Under NYSE Rule 303A.08
PR
03/31RAFAEL  : Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 ..
AQ
03/30RAFAEL  : Enrolls Over150 Patients in Phase 3 Trial of CPI-613 to Treat Leukemia
MT
03/30RAFAEL  : Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 ..
AQ
03/17RAFAEL  : Management's Discussion and Analysis of Financial Condition and Result..
AQ
03/17RAFAEL  : Q2 Loss Widens on Impairment Charge, Names New CEO
MT
03/17RAFAEL HOLDINGS, INC.  : Results of Operations and Financial Condition, Financia..
AQ
03/17RAFAEL  : Earnings Flash (RFL) RAFAEL HOLDINGS Reports Q2 Revenue $959,000
MT
03/17RAFAEL  : Reports Second Quarter Fiscal Year 2021 Results
PR
03/12SECTOR UPDATE : Health Care Stocks Back on Positive Ground Just Ahead of Friday ..
MT
More news